Seroquel IR
ApprovedSmall molecule
OtsukaSeroquel IR is one of 147 small molecule programs targeting Anxiety. It is currently in Approved.
4
Indications
6
Total Trials
0
Active Trials
146
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Elavil
AstraZenecaPhase 3
Daliresp
AstraZenecaPhase 3
Crestor
AstraZenecaPhase 3
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Risperdal
WWim Janssens
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bipolar Disorder1 trial
Major Depressive Disorder1 trial
Alcohol Dependence1 trial
Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety
Completed·—·Phase 4·NCT00352469·20 enrolled
Efficacy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Seroquel IR. EMBL-EBI & Wellcome Sanger Institute.
- [4]